Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2115102 | Cancer Letters | 2007 | 9 Pages |
Abstract
Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP–PCR) assay. We detected KRAS mutations in 9% plasma samples and 0% matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the positive results in a second laboratory by DNA sequencing and found matching codon 12 sequences in blood and tumor in 78% evaluable cases. These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
O. Gautschi, B. Huegli, A. Ziegler, M. Gugger, J. Heighway, D. Ratschiller, P.C. Mack, P.H. Gumerlock, H.J. Kung, R.A. Stahel, D.R. Gandara, D.C. Betticher,